G

Galectin Therapeutics
D

GALT

3.51000
USD
-0.33
(-8.59%)
قبل الجلسة·3.84000USD+0.33000(+9.40%)
حجم التداول
13,969
الربح لكل سهم
-0
العائد الربحي
-
P/E
-7
حجم السوق
231,157,712
أصول ذات صلة المقالات
المزيد

العنوان: Galectin Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.